Nature's Sunshine Products (NATR) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 21, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-34483
Entity Registrant Name	NATURE’S SUNSHINE PRODUCTS, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0327982
Entity Address, Address Line One	2901 Bluegrass Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	341-7900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	NATR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,045,405
Entity Central Index Key	0000275053
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 65,720	$ 60,032
Accounts receivable, net of allowance for doubtful accounts of $122 and $120, respectively	10,474	14,106
Inventories	67,524	67,949
Prepaid expenses and other	10,702	7,420
Total current assets	154,420	149,507
Property, plant and equipment, net	46,080	46,162
Operating lease right-of-use assets	16,152	16,145
Investment securities - trading	718	702
Deferred income tax assets	6,965	6,859
Other assets	10,249	10,403
Total assets	234,584	229,778
Current liabilities:
Accounts payable	8,775	6,349
Accrued volume incentives and service fees	22,611	21,830
Accrued liabilities	28,730	25,591
Deferred revenue	1,128	2,255
Income taxes payable	4,654	4,117
Current portion of operating lease liabilities	4,671	4,266
Current portion of note payable and revolving credit facility	1,007	1,174
Total current liabilities	71,576	65,582
Liability related to unrecognized tax benefits	215	209
Long-term portion of operating lease liabilities	13,382	13,745
Deferred compensation payable	718	702
Deferred income tax liabilities	936	1,439
Other liabilities	1,040	1,054
Total liabilities	87,867	82,731
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,045 and 19,093 shares issued and outstanding, respectively	121,653	121,583
Retained earnings	35,495	34,635
Noncontrolling interest	4,535	4,142
Accumulated other comprehensive loss	(14,966)	(13,313)
Total shareholders’ equity	146,717	147,047
Total liabilities and shareholders’ equity	$ 234,584	$ 229,778

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 122	$ 120
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares outstanding (in shares)	19,045	19,093
Common stock, shares issued (in shares)	19,045	19,093

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net sales	$ 108,634	$ 110,494
Cost of sales	31,692	34,460
Gross profit	76,942	76,034
Operating expenses:
Volume incentives	33,128	34,102
Selling, general and administrative	43,642	40,623
Operating income	172	1,309
Other income (loss), net	1,514	(314)
Income before provision for income taxes	1,686	995
Provision for income taxes	433	3,681
Net income (loss)	1,253	(2,686)
Net income attributable to noncontrolling interests	393	264
Net income (loss) attributable to common shareholders	$ 860	$ (2,950)
Basic and diluted net income (loss) per common share:
Basic earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.05	$ (0.15)
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.04	$ (0.15)
Weighted average basic common shares outstanding (in shares)	19,061	19,573
Weighted average diluted common shares outstanding (in shares)	19,433	19,573

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 1,253	$ (2,686)
Foreign currency translation loss (net of tax)	(1,653)	(975)
Total comprehensive loss	$ (400)	$ (3,661)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021		19,724
Beginning balance at Dec. 31, 2021	$ 161,404	$ 133,382	$ 35,025	$ 3,202	$ (10,205)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	801	$ 801
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		188
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	$ (795)	$ (795)
Repurchase of common stock (in shares)	(451)	(451)
Repurchase of common stock	$ (7,971)	$ (7,971)
Net income (loss)	(2,686)		(2,950)	264
Other comprehensive loss	(975)				(975)
Ending balance (in shares) at Mar. 31, 2022		19,461
Ending balance at Mar. 31, 2022	$ 149,778	$ 125,417	32,075	3,466	(11,180)
Beginning balance (in shares) at Dec. 31, 2022	19,093	19,093
Beginning balance at Dec. 31, 2022	$ 147,047	$ 121,583	34,635	4,142	(13,313)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,058	$ 1,058
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		42
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	$ (165)	$ (165)
Repurchase of common stock (in shares)	(90)	(90)
Repurchase of common stock	$ (823)	$ (823)
Net income (loss)	1,253		860	393
Other comprehensive loss	$ (1,653)				(1,653)
Ending balance (in shares) at Mar. 31, 2023	19,045	19,045
Ending balance at Mar. 31, 2023	$ 146,717	$ 121,653	$ 35,495	$ 4,535	$ (14,966)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 1,253	$ (2,686)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Provision for doubtful accounts	4	6
Depreciation and amortization	2,805	2,766
Non-cash lease expense	932	1,173
Share-based compensation expense	1,058	801
Loss on sale of property, plant and equipment	71	0
Deferred income taxes	(631)	3,844
Purchase of trading investment securities	0	(12)
Proceeds from sale of trading investment securities	31	35
Realized and unrealized (gains) losses on investments	(47)	58
Foreign exchange losses	(1,477)	402
Changes in assets and liabilities:
Accounts receivable	3,649	1,447
Inventories	457	(3,489)
Prepaid expenses and other current assets	(3,266)	(2,518)
Other assets	(11)	(20)
Accounts payable	2,391	(946)
Accrued volume incentives and service fees	781	(464)
Accrued liabilities	2,759	(5,386)
Deferred revenue	(1,142)	(1,632)
Lease liabilities	(900)	(1,031)
Income taxes payable	586	(191)
Liability related to unrecognized tax benefits	6	0
Deferred compensation payable	16	(81)
Net cash provided by (used in) operating activities	9,325	(7,924)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(2,325)	(1,518)
Net cash used in investing activities	(2,325)	(1,518)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments of long-term debt	(318)	(308)
Proceeds from revolving credit facility	433	0
Principal payments of revolving credit facility	(283)	0
Principal payments of related party borrowing	0	(300)
Payments related to tax withholding for net-share settled equity awards	(165)	(795)
Repurchase of common stock	(823)	(7,971)
Net cash used in financing activities	(1,156)	(9,374)
Effect of exchange rates on cash and cash equivalents	(156)	(827)
Net increase (decrease) in cash and cash equivalents	5,688	(19,643)
Cash and cash equivalents at the beginning of the period	60,032	86,184
Cash and cash equivalents at the end of the period	65,720	66,541
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	1,991	1,809
Cash paid for interest	$ 25	$ 45

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of March 31, 2023, and for the three-month periods ended March 31, 2023 and 2022. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations. The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. Noncontrolling Interests Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.4 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, noncontrolling interests were $4.5 million and $4.1 million, respectively. Recent Accounting Pronouncements No new accounting pronouncement issued or effective during the three months ended March 31, 2023, had, or is expected to have, a material impact on our condensed consolidated financial statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 22,183 $ 23,133 Work in progress 1,614 1,713 Finished goods 43,727 43,103 Total inventories $ 67,524 $ 67,949

Investment Securities - Trading

Investment Securities - Trading	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading Our trading securities portfolio totaled $0.7 million at March 31, 2023, and $0.7 million at December 31, 2022, and generated gains of $47,000 and losses of $58,000 for the three months ended March 31, 2023 and 2022, respectively.

Revolving Credit Facility and O

Revolving Credit Facility and Other Obligations	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Revolving Credit Facility and Other Obligations	Revolving Credit Facility and Other Obligations On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022 the credit agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each, subject to the lender's due diligence. The amendment to the Credit Agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (6.39 percent as of March 31, 2023), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. As of March 31, 2023 and December 31, 2022 we had outstanding balances under the Credit Agreement $0.2 million and $0, respectively, included in current portion of note payable within our Condensed Consolidated Balance Sheets. The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of March 31, 2023, we were in compliance with the debt covenants set forth in the Credit Agreement. On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in 36 monthly payments of $0.1 million. The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of March 31, 2023, there was $0.9 million outstanding balance under the Capital Credit Agreement, of which $0.9 million was classified as current.

Net Income (loss) Per Share

Net Income (loss) Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Income (loss) Per Share	Net Income (loss) Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three months ended March 31, 2023 and 2022 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2023 2022 Net income (loss) attributable to common shareholders $ 860 $ (2,950) Basic weighted average shares outstanding 19,061 19,573 Basic earnings (loss) per share attributable to common shareholders $ 0.05 $ (0.15) Diluted shares outstanding: Basic weighted-average shares outstanding 19,061 19,573 Stock-based awards 372 — Diluted weighted-average shares outstanding 19,433 19,573 Diluted earnings (loss) per share attributable to common shareholders $ 0.04 $ (0.15) Dilutive shares excluded from diluted-per-share amounts: Share-based awards 520 — Anti-dilutive shares excluded from diluted-per-share amounts: Share-based awards 102 282 (1) _________________________________________ (1) As a result of the net loss for the three months ended March 31, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the three months ended March 31, 2022 include 282 restricted stock units. Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted- average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Capital Transactions	Capital Transactions Dividends The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors. Share Repurchase Program On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022 we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the three months ended March 31, 2023, we repurchased 90,000 shares of our common stock for $0.8 million. For the three months ended March 31, 2022, we repurchased 451,000 shares of our common stock for $8.0 million. At March 31, 2023, the remaining balance available for repurchases under the program was $23.2 million. Share-Based Compensation During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan. The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. Stock Options Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the three-month period ended March 31, 2023, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2022 143 $ 12.72 $ 5.28 Granted — — — Forfeited or canceled (16) 11.98 — Exercised — — — Options outstanding at March 31, 2023 127 $ 12.81 $ 5.16 There was no share-based compensation expense from stock options for the three- month periods ended March 31, 2023 and 2022. As of March 31, 2023 and December 31, 2022, there was no unrecognized share-based compensation expense related to the grants described above. At March 31, 2023, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 127,000 shares of common stock was $0. At December 31, 2022, the aggregate intrinsic value of outstanding and exercisable options to purchase 143,000 shares of common stock was $0. For the three-month period ended March 31, 2023, no shares of common stock were issued upon the exercise of stock options. For the three months ended March 31, 2022, we issued 29,000 shares of common stock upon the exercise of stock options at an average exercise price of $9.17 per share. The aggregate intrinsic value of options exercised during the three-month periods ended March 31, 2023 and 2022, was $0 and $0.3 million, respectively. For the three-month periods ended March 31, 2023 and 2022, the Company recognized $0 and $0.1 million of tax benefits from the exercise of stock options, respectively. As of March 31, 2023 and December 31, 2022, we did not have any unvested stock options outstanding. Restricted Stock Units Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to adjusted EBITDA growth, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At March 31, 2023 and December 31, 2022, there were 106,000 and 94,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period. Restricted stock unit activity for the three-month period ended March 31, 2023, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2022 1,091 $ 10.76 Granted — — Forfeited (45) 2.80 Issued (57) 12.30 Restricted Stock Units outstanding at March 31, 2023 989 11.04 During the three-month period ended March 31, 2023, no RSUs were granted under the 2012 Incentive Plan. Share-based compensation expense related to time-based RSUs for the three-month periods ended March 31, 2023 and 2022, was approximately $0.8 million and $0.5 million, respectively. As of March 31, 2023 and December 31, 2022, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.2 million and $3.0 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.5 years. Share-based compensation expense related to performance-based RSUs for the three-month periods ended March 31, 2023 and 2022, was $0.3 million and $0.3 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $4.5 million of potential share-based compensation expense. We currently expect to recognize an additional $2.2 million of that potential share based compensation expense.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. The geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2023 2022 Net sales: Asia $ 46,345 $ 46,110 Europe 21,405 21,777 North America 34,648 35,981 Latin America and Other 6,236 6,626 Total net sales 108,634 110,494 Contribution margin (1): Asia 21,951 21,939 Europe 6,536 4,373 North America 12,861 12,719 Latin America and Other 2,466 2,901 Total contribution margin 43,814 41,932 Selling, general and administrative expenses (2) 43,642 40,623 Operating income 172 1,309 Other loss, net 1,514 (314) Income before provision for income taxes $ 1,686 $ 995 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $3.7 million and $4.9 million for the three-month periods ended March 31, 2023 and 2022, respectively. These service fees are included in selling, general and administrative expenses. From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three-month periods ended March 31, 2023 and 2022, as follows (dollar amounts in thousands): Three Months Ended 2023 2022 Net sales: United States $ 31,986 $ 33,229 Taiwan 14,175 9,750 South Korea 11,240 13,653 Other 51,233 53,862 $ 108,634 $ 110,494 Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended 2023 2022 Asia General health $ 13,764 $ 12,986 Immune 462 1,344 Cardiovascular 14,895 13,630 Digestive 9,422 9,036 Personal care 1,341 2,543 Weight management 6,461 6,571 46,345 46,110 Europe General health $ 9,174 $ 9,196 Immune 2,284 2,631 Cardiovascular 2,519 2,633 Digestive 5,738 5,591 Personal care 1,177 1,233 Weight management 513 493 21,405 21,777 North America General health $ 15,534 $ 15,314 Immune 4,320 4,872 Cardiovascular 3,588 3,842 Digestive 8,731 8,594 Personal care 1,464 2,175 Weight management 1,011 1,184 34,648 35,981 Latin America and Other General health $ 1,637 $ 1,818 Immune 744 761 Cardiovascular 466 357 Digestive 2,885 2,841 Personal care 351 641 Weight management 153 208 6,236 6,626 $ 108,634 $ 110,494 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 42,424 $ 42,389 Other 3,656 3,773 Total property, plant and equipment, net $ 46,080 $ 46,162 Total assets per segment is set forth below (dollar amounts in thousands): March 31, December 31, Assets: Asia $ 100,592 $ 95,362 Europe 18,610 15,773 North America 107,507 112,319 Latin America and Other 7,875 6,324 Total assets $ 234,584 $ 229,778

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 31, 2023 and 2022, our provision for income taxes, as a percentage of income before income taxes was 25.7 percent and 369.9 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2023, was primarily attributed to an increase in tax liability related to foreign operations which are treated as a branch for US tax purposes and current year foreign losses that presently do not provide future tax benefit, partially offset by favorable adjustments to deferred tax assets and foreign tax credits. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2022, was primarily attributed to recording a valuation allowance against deferred tax assets for which we do not expect to receive a benefit. The difference between the effective tax rate for the three months ended March 31, 2023 compared to March 31, 2022 is primarily caused by recording a valuation allowance in the prior period against deferred tax assets for which we do not expect to receive a benefit. Our U.S. federal income tax returns for 2019 through 2021 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2017 through 2022. As of March 31, 2023 and December 31, 2022, we have accrued $0.2 million and $0.2 million, respectively, related to unrecognized tax positions. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of March 31, 2023 and December 31, 2022, accrued liabilities were $0.3 million and $0.3 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.9 million. Other Litigation

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of March 31, 2023 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 718 $ — $ — $ 718 Total assets measured at fair value on a recurring basis $ 718 $ — $ — $ 718 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2022 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 702 $ — $ — $ 702 Total assets measured at fair value on a recurring basis $ 702 $ — $ — $ 702 Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the three months ended March 31, 2023 and for the year ended December 31, 2022, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3).

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue Recognition Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive. Amounts billed to customers for shipping and handling are reported as a component of net sales. Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.

Synergy Japan Loss

Synergy Japan Loss	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Synergy Japan Loss	Synergy Japan LossOn February 17, 2023, we became aware that Synergy Worldwide Japan G.K., a Japan entity and wholly owned subsidiary of the Company (“Synergy Japan”), was the victim of a criminal scheme involving employee impersonation and fraudulent requests targeting Synergy Japan. The criminal scheme resulted in a series of fraudulently induced wire transfers between February 1, 2023, and February 17, 2023 totaling $4.8 million. We promptly launched an investigation, led by an independent third party, to determine the full extent of the fraud scheme and related potential exposure. We self-discovered this fraudulent activity and promptly initiated contact with our bank as well as appropriate law enforcement authorities in an effort to, among other things, recover the transferred funds. To date, we have not found any evidence of additional fraudulent activity and do not believe the incident resulted in any unauthorized access to confidential consumer information or other data maintained by the Company. As a result of this matter, we incurred investigation and other professional fees of $1.0 million, which along with the initial $4.8 million loss, were recorded in Selling, General and Administrative expense for the three months ended March 31, 2023. We do not expect this incident to otherwise have a material impact on our business.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of March 31, 2023, and for the three-month periods ended March 31, 2023 and 2022. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements No new accounting pronouncement issued or effective during the three months ended March 31, 2023, had, or is expected to have, a material impact on our condensed consolidated financial statements.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 22,183 $ 23,133 Work in progress 1,614 1,713 Finished goods 43,727 43,103 Total inventories $ 67,524 $ 67,949

Net Income (loss) Per Share (Ta

Net Income (loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three months ended March 31, 2023 and 2022 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2023 2022 Net income (loss) attributable to common shareholders $ 860 $ (2,950) Basic weighted average shares outstanding 19,061 19,573 Basic earnings (loss) per share attributable to common shareholders $ 0.05 $ (0.15) Diluted shares outstanding: Basic weighted-average shares outstanding 19,061 19,573 Stock-based awards 372 — Diluted weighted-average shares outstanding 19,433 19,573 Diluted earnings (loss) per share attributable to common shareholders $ 0.04 $ (0.15) Dilutive shares excluded from diluted-per-share amounts: Share-based awards 520 — Anti-dilutive shares excluded from diluted-per-share amounts: Share-based awards 102 282 (1) _________________________________________ (1) As a result of the net loss for the three months ended March 31, 2022, no potentially dilutive securities are included in the calculation of diluted loss per share because such effect would be anti-dilutive. Potentially dilutive securities for the three months ended March 31, 2022 include 282 restricted stock units.

Capital Transactions (Tables)

Capital Transactions (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of stock option activity	Stock option activity for the three-month period ended March 31, 2023, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2022 143 $ 12.72 $ 5.28 Granted — — — Forfeited or canceled (16) 11.98 — Exercised — — — Options outstanding at March 31, 2023 127 $ 12.81 $ 5.16
Schedule of restricted stock unit activity	Restricted stock unit activity for the three-month period ended March 31, 2023, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2022 1,091 $ 10.76 Granted — — Forfeited (45) 2.80 Issued (57) 12.30 Restricted Stock Units outstanding at March 31, 2023 989 11.04

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2023 2022 Net sales: Asia $ 46,345 $ 46,110 Europe 21,405 21,777 North America 34,648 35,981 Latin America and Other 6,236 6,626 Total net sales 108,634 110,494 Contribution margin (1): Asia 21,951 21,939 Europe 6,536 4,373 North America 12,861 12,719 Latin America and Other 2,466 2,901 Total contribution margin 43,814 41,932 Selling, general and administrative expenses (2) 43,642 40,623 Operating income 172 1,309 Other loss, net 1,514 (314) Income before provision for income taxes $ 1,686 $ 995 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
Schedule of consolidated net sales revenue by geographical locations	From an individual country/region perspective, the United States, South Korea and Taiwan comprise 10 percent or more of consolidated net sales for the three-month periods ended March 31, 2023 and 2022, as follows (dollar amounts in thousands): Three Months Ended 2023 2022 Net sales: United States $ 31,986 $ 33,229 Taiwan 14,175 9,750 South Korea 11,240 13,653 Other 51,233 53,862 $ 108,634 $ 110,494
Schedule of revenue generated by each of the Company's product lines	Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended 2023 2022 Asia General health $ 13,764 $ 12,986 Immune 462 1,344 Cardiovascular 14,895 13,630 Digestive 9,422 9,036 Personal care 1,341 2,543 Weight management 6,461 6,571 46,345 46,110 Europe General health $ 9,174 $ 9,196 Immune 2,284 2,631 Cardiovascular 2,519 2,633 Digestive 5,738 5,591 Personal care 1,177 1,233 Weight management 513 493 21,405 21,777 North America General health $ 15,534 $ 15,314 Immune 4,320 4,872 Cardiovascular 3,588 3,842 Digestive 8,731 8,594 Personal care 1,464 2,175 Weight management 1,011 1,184 34,648 35,981 Latin America and Other General health $ 1,637 $ 1,818 Immune 744 761 Cardiovascular 466 357 Digestive 2,885 2,841 Personal care 351 641 Weight management 153 208 6,236 6,626 $ 108,634 $ 110,494
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 42,424 $ 42,389 Other 3,656 3,773 Total property, plant and equipment, net $ 46,080 $ 46,162
Schedule of assets per segment	Total assets per segment is set forth below (dollar amounts in thousands): March 31, December 31, Assets: Asia $ 100,592 $ 95,362 Europe 18,610 15,773 North America 107,507 112,319 Latin America and Other 7,875 6,324 Total assets $ 234,584 $ 229,778

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of the company's hierarchy for assets measured at fair value on a recurring basis	The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of March 31, 2023 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 718 $ — $ — $ 718 Total assets measured at fair value on a recurring basis $ 718 $ — $ — $ 718 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2022 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 702 $ — $ — $ 702 Total assets measured at fair value on a recurring basis $ 702 $ — $ — $ 702

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Increase (decrease) in noncontrolling interest	$ 400	$ 300
Noncontrolling interest	$ 4,535		$ 4,142

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 22,183	$ 23,133
Work in progress	1,614	1,713
Finished goods	43,727	43,103
Total inventories	$ 67,524	$ 67,949

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 718		$ 702
Debt securities, trading, realized gains (losses)	$ 47	$ (58)

Revolving Credit Facility and_2

Revolving Credit Facility and Other Obligations (Details) $ in Millions	Jun. 23, 2022 USD ($) borrowing	Nov. 19, 2020 USD ($) payment	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 21, 2020 USD ($)	Jul. 11, 2017 USD ($)
Revolving credit facility | Bank of America Credit Agreement
Long-term debt
Maximum borrowing capacity						$ 25
Potential increase in maximum borrowing capacity	$ 25
Number of separate increases | borrowing	3
Potential increase in maximum borrowing capacity, per occurrence	$ 5
Annual commitment fee	0.25%
Long-term line of credit			$ 0.2	$ 0
Revolving credit facility | LIBOR | Bank of America Credit Agreement
Long-term debt
Margin on variable rate	1.50%
Effective interest rate			6.39%
Line of Credit | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Maximum borrowing capacity					$ 6
Long-term line of credit		$ 3.7	$ 0.9
Number of monthly payments | payment		36
Periodic payment		$ 0.1
Line of credit, outstanding, current			$ 0.9
Line of Credit | Indicative Index | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Effective interest rate			3%

Net Income (loss) Per Share (De

Net Income (loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net income (loss) attributable to common shareholders	$ 860	$ (2,950)
Basic weighted average shares outstanding (in shares)	19,061	19,573
Basic earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.05	$ (0.15)
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	19,061	19,573
Stock-based awards (in shares)	372	0
Diluted weighted-average shares outstanding (in shares)	19,433	19,573
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.04	$ (0.15)
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	520	0
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	102	282
Potentially dilutive shares included in the calculation of diluted earnings per share		0

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details) - USD ($)		3 Months Ended		12 Months Ended
	May 05, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2015	Dec. 31, 2022	Mar. 08, 2022	Mar. 10, 2021	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount						$ 30,000,000	$ 15,000,000
Repurchase of common stock (in shares)		90,000	451,000
Repurchase of common stock		$ 823,000	$ 7,971,000
Stock repurchase program, remaining authorized repurchase amount		23,200,000
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)								1,500,000
Additional number of shares authorized under the plan (in shares)	2,000,000			1,500,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		0	$ 0
Unrecognized share-based compensation expense		$ 0			$ 0
Options outstanding (in shares)		127,000			143,000
Aggregate intrinsic value, outstanding		$ 0			$ 0
Exercised (in shares)		0	29,000
Exercised (in dollars per share)		$ 0	$ 9.17
Aggregate intrinsic values of options exercised		$ 0	$ 300,000
Tax benefit from the exercise of stock options		$ 0	100,000
Time-based stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one (as a percent)		6%
Operating income margin, two (as a percent)		8%
Operating income margin, three (as a percent)		10%
Unvested stock options outstanding (in shares)		0			0
Performance based stock options operating income margins | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period		1 year
Performance based stock options operating income margins | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period		1 year 3 months
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 800,000	$ 500,000
Unrecognized share-based compensation expense		$ 2,200,000			$ 3,000,000
Weighted-average period over which the remaining compensation cost is expected to be recognized		1 year 6 months
Minimum withholding requirements (in shares)		15,000	60,000
RSUs | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		0
RSUs | Minimum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		12 months
RSUs | Maximum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		36 months
RSUs | Director | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restriction period for issuance of shares		2 years
Nonvested subject to restriction period (in shares)		106,000			94,000
Performance-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 300,000	$ 300,000
Share based compensation potential compensation expense to be recognized		2,200,000
Performance-Based Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation potential compensation expense to be recognized		$ 4,500,000

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - Stock options - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of Shares
Options outstanding at the beginning of the period (in shares)	143,000
Granted (in shares)	0
Forfeited or canceled (in shares)	(16,000)
Exercised (in shares)	0	(29,000)
Options outstanding at the end of the period (in shares)	127,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 12.72
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	11.98
Exercised (in dollars per share)	0	$ 9.17
Options outstanding at the end of the period (in dollars per share)	12.81
Weighted Average Grant Date Fair Value
Options outstanding at the beginning of the period (in dollars per share)	5.28
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	0
Options outstanding at the beginning of the period (in dollars per share)	$ 5.16

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of Shares
Restricted Stock Units outstanding, beginning balance (in shares) | shares	1,091,000
Granted (in shares) | shares	0
Forfeited (in shares) | shares	(45,000)
Issued (in shares) | shares	(57,000)
Restricted Stock Units outstanding, ending balance (in shares) | shares	989,000
Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding, beginning balance (in dollars per share) | $ / shares	$ 10.76
Granted (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	2.80
Issued (in dollars per share) | $ / shares	12.30
Restricted Stock Units outstanding, ending balance (in dollars per share) | $ / shares	$ 11.04

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Segment information
Number of business segments | segment	4
Net sales:
Total net sales revenue	$ 108,634	$ 110,494
Contribution margin:
Total contribution margin	43,814	41,932
Selling, general and administrative expenses	43,642	40,623
Operating income	172	1,309
Other loss, net	1,514	(314)
Income before provision for income taxes	1,686	995
Total property, plant and equipment, net	46,080		$ 46,162
Total assets	234,584		229,778
CHINA
Contribution margin:
Selling, general and administrative expenses	3,700	4,900
United States
Net sales:
Total net sales revenue	31,986	33,229
Contribution margin:
Total property, plant and equipment, net	42,424		42,389
Taiwan
Net sales:
Total net sales revenue	14,175	9,750
South Korea
Net sales:
Total net sales revenue	11,240	13,653
Other
Net sales:
Total net sales revenue	51,233	53,862
Contribution margin:
Total property, plant and equipment, net	3,656		3,773
Asia
Net sales:
Total net sales revenue	46,345	46,110
Contribution margin:
Total contribution margin	21,951	21,939
Total assets	100,592		95,362
Asia | General health
Net sales:
Total net sales revenue	13,764	12,986
Asia | Immune
Net sales:
Total net sales revenue	462	1,344
Asia | Cardiovascular
Net sales:
Total net sales revenue	14,895	13,630
Asia | Digestive
Net sales:
Total net sales revenue	9,422	9,036
Asia | Personal care
Net sales:
Total net sales revenue	1,341	2,543
Asia | Weight management
Net sales:
Total net sales revenue	6,461	6,571
Europe
Net sales:
Total net sales revenue	21,405	21,777
Contribution margin:
Total contribution margin	6,536	4,373
Total assets	18,610		15,773
Europe | General health
Net sales:
Total net sales revenue	9,174	9,196
Europe | Immune
Net sales:
Total net sales revenue	2,284	2,631
Europe | Cardiovascular
Net sales:
Total net sales revenue	2,519	2,633
Europe | Digestive
Net sales:
Total net sales revenue	5,738	5,591
Europe | Personal care
Net sales:
Total net sales revenue	1,177	1,233
Europe | Weight management
Net sales:
Total net sales revenue	513	493
North America
Net sales:
Total net sales revenue	34,648	35,981
Contribution margin:
Total contribution margin	12,861	12,719
Total assets	107,507		112,319
North America | General health
Net sales:
Total net sales revenue	15,534	15,314
North America | Immune
Net sales:
Total net sales revenue	4,320	4,872
North America | Cardiovascular
Net sales:
Total net sales revenue	3,588	3,842
North America | Digestive
Net sales:
Total net sales revenue	8,731	8,594
North America | Personal care
Net sales:
Total net sales revenue	1,464	2,175
North America | Weight management
Net sales:
Total net sales revenue	1,011	1,184
Latin America and Other
Net sales:
Total net sales revenue	6,236	6,626
Contribution margin:
Total contribution margin	2,466	2,901
Total assets	7,875		$ 6,324
Latin America and Other | General health
Net sales:
Total net sales revenue	1,637	1,818
Latin America and Other | Immune
Net sales:
Total net sales revenue	744	761
Latin America and Other | Cardiovascular
Net sales:
Total net sales revenue	466	357
Latin America and Other | Digestive
Net sales:
Total net sales revenue	2,885	2,841
Latin America and Other | Personal care
Net sales:
Total net sales revenue	351	641
Latin America and Other | Weight management
Net sales:
Total net sales revenue	$ 153	$ 208

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	25.70%	369.90%
Liability related to unrecognized tax benefits	$ 0.2		$ 0.2

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) claim	Dec. 31, 2022 USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	300,000	$ 300,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	400,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	2,900,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 500,000	$ 600,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Total
Fair value
Investment securities - trading	$ 718	$ 702
Total assets measured at fair value on a recurring basis	718	702
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	718	702
Total assets measured at fair value on a recurring basis	718	702
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 segment product_category
Revenue from Contract with Customer [Abstract]
Refund period	90 days
Number of principal categories of products | product_category	6
Number of business segments | segment	4

Synergy Japan Loss (Details)

Synergy Japan Loss (Details) - Fraud Expense - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Feb. 17, 2023	Mar. 31, 2023
Commitments and contingencies
Provision for losses	$ 4.8	$ 4.8
Investigation and other professional fees		$ 1